Integrated microbial biologics development and manufacturing
Agilent Advanced Therapeutics delivers end-to-end microbial biologics development and GMP manufacturing to support programs from early process design through commercial supply.
Our integrated capabilities combine strain and fermentation optimization, scalable upstream and downstream processing, and comprehensive analytical characterization under a harmonized quality system. With stainless-steel and single-use bioreactors, tech transfer support, and in-house QC testing, we reduce complexity, improve consistency, and help biologics developers advance with speed and confidence.
End-to-end biomanufacturing—Process and analytical development through commercial-scale production under one quality system.
Advanced fermentation capacity—Two 17,000 L stainless-steel fermenters plus 100 L and 1,000 L single-use units for flexible scaling.
Refolding and purification excellence—12,000 L refolding tank and 1.4 m chromatography column for efficient protein recovery.
Parallel development approach—Analytical method qualification runs alongside scale-up to reduce timelines to GMP manufacture.
Broad expression systems—Expertise in <i>E. coli, S.</i> cerevisiae, and <i>Pichia pastoris</i> for proteins, enzymes, and antibody fragments.
Operational reliability—24/7 staffed operations and risk-based program onboarding ensure consistency and control.
Biologics
Microbial biologics from process development through GMP manufacturing
Find helpful answers to common questions as you evaluate and advance your program
What types of biologics do you manufacture?
Recombinant proteins, enzymes, antibody fragments, and peptides using microbial systems such as E. coli, yeast, and Pichia pastoris.
What fermentation scales do you offer?
100 L and 1,000 L single-use bioreactors, and 17,000 L stainless-steel fermentation for commercial supply.
How do you support tech transfer?
Structured tech-transfer workflows with process characterization, comparability assessments, and risk mapping.
style
id
faqs
Browse the latest news on Advanced Therapeutics manufacturing
BIOVECTRA Is Honored with 2025 CDMO Leadership Award
BIOVECTRA, a part of Agilent Technologies Inc., proudly announces it is the recipient of the 2025 Outsourced Pharma CDMO Leadership Award in the category of biologics. The award recognizes BIOVECTRA’s performance in key areas such as quality, reliability, and technical capability.
3/6/2025
Agilent Completes Acquisition of BIOVECTRA
Agilent Technologies announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.
9/20/2024
Agilent Investing $725 Million to Expand Nucleic Acid-Based Therapeutics Manufacturing
Agilent Technologies is investing approximately $725 million to double manufacturing capacity of therapeutic nucleic acids in response to rapid growth of the $1 billion market and strong demand for the company’s high-quality active pharmaceutical ingredients (APIs).
1/10/2023
id
news
Innovative sustainability in water, waste, and energy
The Frederick facility integrates sustainable practices, like closed-cell cooling towers and reverse osmosis systems that save over 16 million gallons of water annually. A solar photovoltaic array generates 500 MWh of clean energy to offset utility demand. Waste reduction initiatives include acetonitrile recovery and destruction of dilute organics.
id
sustainability
Explore ways to connect with the Advanced Therapeutics team
Have questions or need a quote? Our manufacturing experts are here to help.
Get support from experienced specialists dedicated to your program’s success.
Upcoming events
See where the Agilent Advanced Therapeutics team will be next. Explore our upcoming conferences, tradeshows, and speaking engagements, and connect with us in person.
